Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, Kates MR, Bivalacqua TJ, Tran PT, Song DY, Baras AS, Matoso A, Choi W, Smith KN, Pardoll DM, Marchionni L, McGuire B, Grace Phelan M, Johnson BA 3rd, O'Neal T, McConkey DJ, Rose TL, Bjurlin M, Lim EA, Drake CG, McKiernan JM, Deutsch I, Anderson CB, Lamm DL, Geynisman DM, Plimack ER, Hallman MA, Horwitz EM, Al-Saleem E, Chen DYT, Greenberg RE, Kutikov A, Guo G, Masterson TA, Adra N, Kaimakliotis HZ. Hahn NM, et al. Among authors: johnson ba 3rd. Eur Urol. 2023 Jun;83(6):486-494. doi: 10.1016/j.eururo.2023.01.017. Epub 2023 Jan 28. Eur Urol. 2023. PMID: 36717286 Clinical Trial.
Targeting neoantigens to augment antitumour immunity.
Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Among authors: johnson ba 3rd. Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. Nat Rev Cancer. 2017. PMID: 28835723 No abstract available.
Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Johnson BA 3rd, et al. Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Clin Cancer Res. 2017. PMID: 28373364 Free PMC article. Review.
Targeting neoantigens to augment antitumour immunity.
Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Among authors: johnson ba 3rd. Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Nat Rev Cancer. 2017. PMID: 28233802 Free PMC article. Review.
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Yarchoan M, Ma C, Troxel AB, Stopenski SJ, Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA 3rd, Chen EY, Feldman MD, Brose MS. Yarchoan M, et al. Among authors: johnson ba 3rd. Horm Cancer. 2016 Jun;7(3):188-95. doi: 10.1007/s12672-016-0253-6. Epub 2016 Mar 18. Horm Cancer. 2016. PMID: 26994002 Free PMC article.
Physiologic control of IDO competence in splenic dendritic cells.
Baban B, Chandler PR, Johnson BA 3rd, Huang L, Li M, Sharpe ML, Francisco LM, Sharpe AH, Blazar BR, Munn DH, Mellor AL. Baban B, et al. Among authors: johnson ba 3rd. J Immunol. 2011 Sep 1;187(5):2329-35. doi: 10.4049/jimmunol.1100276. Epub 2011 Aug 3. J Immunol. 2011. PMID: 21813777 Free PMC article.
13 results